Aeterna Zentaris Provides Update on Timing for Annual Meeting of Shareholders and Due Bill Redemption Date

Core Viewpoint - Aeterna Zentaris Inc. is seeking a court order to extend the deadline for holding its annual shareholder meeting to no later than July 31, 2024, to allow former Ceapro Inc. shareholders to participate in the meeting and vote on key matters related to the upcoming merger [1][2]. Group 1: Court Application and Meeting Details - The application for the extension will be heard on June 3, 2024, at 11:00 a.m. via videoconference [1]. - Aeterna has received an extension from the Toronto Stock Exchange to hold its annual meeting by July 31, 2024 [3]. - The annual meeting will include votes on the new name and director nominees for the combined company following the transaction with Ceapro [2]. Group 2: Transaction with Ceapro Inc. - Aeterna is in the process of completing a transaction with Ceapro Inc., which is expected to close around June 3, 2024, subject to necessary approvals [2]. - The extension is aimed at ensuring that former Ceapro shareholders can attend and vote at the annual meeting [2]. Group 3: Company Overview - Aeterna Zentaris is a specialty biopharmaceutical company focused on developing and commercializing a diverse portfolio of pharmaceutical and diagnostic products [4]. - The company's lead product, macimorelin, is the first FDA and European Commission approved oral test for diagnosing adult growth hormone deficiency [4]. - Aeterna is also developing therapeutic assets for various conditions, including neuromyelitis optica spectrum disorder, Parkinson's disease, hypoparathyroidism, and amyotrophic lateral sclerosis [5].